Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant disease. 1992

X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
Department of Clinical Biochemistry (Unit for Cancer Research). Hospital ClĂ­nic i Provincial, Barcelona, Spain.

TAG-72 is a tumor-associated antigen identified by the monoclonal antibody B72.3. Serum levels of TAG-72 were measured in patients with non-malignant and malignant disease. TAG-72 is not a specific marker of cancer and slightly elevated levels of this antigen can also be detected in the serum of healthy subjects. However, our results show that specificity (92%) and positive predictive value (86%) of this marker are very high. TAG-72 levels above the cut-off limit of 6 U/mL were found in patients with tumors of various organs, including gastrointestinal, ovarian, lung and breast cancer. TAG-72 assay sensitivity is related to tumor stage with values being highest with advanced disease, especially in patients with gastric cancer and lung adenocarcinoma.

UI MeSH Term Description Entries
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
January 1990, Oncology,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
September 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
April 1993, The Journal of clinical endocrinology and metabolism,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
January 1990, The Journal of nuclear medicine and allied sciences,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
July 1990, British journal of cancer,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
May 1989, International journal of cancer,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
January 2001, Oncology reports,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
April 1990, Revista clinica espanola,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
December 1992, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
X Filella, and R Molina, and J Jo, and J L Bedini, and J Joseph, and A M Ballesta
October 1989, Human pathology,
Copied contents to your clipboard!